The Archive · 7 posts
GSK PLC: A global healthcare innovator! 🌍 Explore GSK's breakthroughs in pharmaceuticals, vaccines, and consumer healthcare on the LSE. 🚀
GSK has completed its Nuvalent acquisition, gaining three lung cancer assets in a deal carrying an ÂŁ8 billion equity value.
July 15, 2026
Showing 6 of 7 posts
GSK acquires 35Pharma for $950M, adding potential best-in-class pulmonary hypertension drug HS235 to its pipeline.
JoshuaApril 15, 2026
GSK's $2.2bn acquisition of RAPT Therapeutics bolsters its immunology pipeline with a promising long-acting anti-IgE treatment for food allergies.
JoshuaMarch 4, 2026
GSK bets $950M on 35Pharma's HS235 for pulmonary hypertension, a drug with reduced bleeding risk and metabolic perks.
JoshuaFebruary 25, 2026
GSK acquires RAPT Therapeutics for $2.2bn, gaining a long-acting food allergy drug with 12-week dosing that transforms management for high-risk patients.
JoshuaJanuary 20, 2026
GSK upgrades 2025 outlook after a robust Q3, fueled by Specialty Medicines surge and strong vaccine sales outside the US.
JoshuaOctober 29, 2025
GSK & Hengrui Pharma partner to co-develop 12 novel drugs, led by COPD therapy HRS-9821. $500M upfront + $12B potential milestones in strategic biopharma play.
JoshuaJuly 28, 2025
February 25, 2026